DX-88 inhibitor of human plasma kallikrein regulatory update

FDA placed on clinical hold the Phase II EDEMA2 trial of DYAX's DX-88 recombinant kallikrein inhibitor protein to treat hereditary angioedema (HAE), pending additional

Read the full 245 word article

How to gain access

Continue reading with a
two-week free trial.